Chundsell Medicals seeks 20.0 MSEK at a pre‐money valuation of 89.7 MSEK, entailing 18.2% ownership and 16.5% ownership fully diluted. The proceeds are intended to support and accelerate our commercialisation process.

XVIVO Perfusion is a medical technology company which develops and markets solutions and systems for assessing the usability of organs, enabling the treatment of organs and maintaining organs in good condition outside the body pending transplantation.

Spago Nanomedical is a public company listed on AktieTorget. Here you will find the latest press releases and financial information. Please contact us for further information.

HealthCap is a European venture capital firm investing exclusively and globally in life sciences. The investment strategy focuses on diseases with high unmet medical needs and breakthrough therapies that have the potential to be transformative and change medical practice, and the lives of patients suffering these conditions.

The Sarsia Seed Management team comes from a wide variety of backgrounds with a collective expertise which is extensive not only with respect to the various investment areas on which the fund focuses, but also with respect to best practice/effective fund administration.